Metastatic melanoma: which BRAF/MEK inhibitor combination is best?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Indirect comparison of dabrafenib (Tafinlar) plus trametinib (Mekinist) with vemurafenib (Zelboraf) plus cobimetinib (Cotellic) suggests the 2 combinations have similar efficacy in metastatic melanoma, but adverse events are lower with dabrafenib plus trametinib.
Why this matters
These findings can help providers in the decision-making process when they are evaluating available options of BRAF/MEK inhibitor combinations for this population.
As there are no head-to-head studies, an indirect comparison was performed between dabrafenib plus trametinib and vemurafenib plus cobimetinib; 2 randomized trials were identified (dabrafenib plus trametinib vs vemurafenib with 704 patients and vemurafenib plus cobimetinib vs vemurafenib plus placebo with 495 patients).